About Exonics
Exonics is a Healthcare company based in Boston (United States) founded in 2016, and was acquired by Vertex Pharmaceuticals in June 2019. CRISPRCas-9 therapies for Duchenne Muscular Dystrophy are developed. Exonics has raised $67.04 million across 3 funding rounds from investors including Vertex Pharmaceuticals, The Column Group and CureDuchenne. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Denali Therapeutics and Ultragenyx; 3 of its 3 listed competitors have raised funding.
Company details
Exonics was founded in 2016 as a biotech spin-out from the University of Texas Southwestern Medical Center, focusing on gene editing for rare diseases. CRISPRCas-9 technologies are utilized to target Duchenne Muscular Dystrophy mutations, with AAV delivery tested in mouse models showing dystrophin restoration. Seed funding of 5 million was secured in 2017 from CureDuchenne Ventures. Operations are based in Boston, United States.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website exonicstx.com
- Acquired by Vertex Pharmaceuticals (Jun 2019)
- Total Equity Funding$67.04M (USD)
in 3 rounds
- Latest Funding Round$22.04M (USD), Series A
Nov 2018
- InvestorsVertex Pharmaceuticals
& 2 more
- Acquired byVertex Pharmaceuticals
(Jun 2019)
Funding Insights of Exonics
Exonics has successfully raised a total of $67.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22.04 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.04M
- Total Rounds 3
- Last Round Series A — $22.04M
- First Round $5M
(Feb 2017)
- Investors Count 2
All 3 funding rounds of Exonics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $22.04M | Series A | – | – | |
| Nov 2017 | $40M | Series A | – | TCG | – |
| Feb 2017 | $5M | Seed | – | CureDuchenne | – |
3 investors in total: 3 institutional.
Investors in Exonics
Exonics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, The Column Group and CureDuchenne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Nonprofit organization funding research and providing support for Duchenne patients. | 2009 | cureduchenne.org | Newport Beach, United States | |
Developer of drugs for the treatment of multiple disorders | 1989 | vrtx.com | United States |
Investor details for Exonics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Exonics
4 dated milestones of Exonics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Exonics is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series A, of $22.0M.
- Exit Acquired by Vertex Pharmaceuticals.
Competitors of Exonics
Exonics has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Denali Therapeutics and Ultragenyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. |
Detailed competitors of Exonics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Exonics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exonics
Complete news archive for Exonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exonics
Exonics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Exonics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Exonics is a funded company, having raised a total of $67.04M across 3 funding rounds to date. The company's 1st funding round was a Seed of $5M, raised on Feb 2017.
Exonics was founded in 2016 as a biotech spin-out from the University of Texas Southwestern Medical Center, focusing on gene editing for rare diseases. CRISPRCas-9 technologies are utilized to target Duchenne Muscular Dystrophy mutations, with AAV delivery tested in mouse models showing dystrophin restoration. Seed funding of 5 million was secured in 2017 from CureDuchenne Ventures. Operations are based in Boston, United States.
Exonics's top competitors include Alnylam, Denali Therapeutics and Ultragenyx.
Exonics has 3 investors. Key investors include Vertex Pharmaceuticals, The Column Group, and CureDuchenne.
Yes. Exonics was acquired by Vertex Pharmaceuticals in June 2019.